SCHEMBL9901142

SCHEMBL9901142

O=CCN1CCc2cc(Br)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HTR2A P28223 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
NFKB1 P19838 1/20 0.42
HIF1A Q16665 1/20 0.42
LMNA P02545 1/20 0.41
PMP22 Q01453 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GFER P55789 1/20 0.41
SLC22A12 Q96S37 1/20 0.41
SRD5A1 P18405 1/20 0.40
ABHD6 Q9BV23 1/20 0.40
ROCK1 Q13464 1/20 0.40
AR P10275 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5970924 0.91 HDAC1 (0.50) HDAC1HDAC8HDAC6LMNASLC22A12
SCHEMBL16370572 0.81 ATAD2 (0.44) GFERPDK1PDK2PDK3PDK4
SCHEMBL3654900 0.80 PRMT5 (0.51) SRD5A1
SCHEMBL932044 0.79 S1PR1 (0.39) HDAC1HDAC8HDAC6HTR2CHTR2B
SCHEMBL28942211 0.78 HDAC1 (0.44) HDAC1HDAC8HDAC6MEN1USP2
SCHEMBL12509817 0.78 HSD17B3 (0.55) HDAC1HDAC8HDAC6HTR2AHTR2C
SCHEMBL27787864 0.77 HDAC1 (0.43) HDAC1HDAC8HDAC6HTR2AHTR2C
SCHEMBL3656429 0.77 PARP1 (0.42) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL466270 0.76 ALDH1A1 (0.63) LMNAMEN1USP2ALDH1A1CDK4
SCHEMBL2594028 0.76 CA1 (0.50) ROCK1MEN1ALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140121208-A1 Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-01 US disclosed
WO-2011072241-A9 4-OXO-1H-QUINOLINE-3-CARBOXAMIDES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121208-A1 Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases CFTR, SLC26A4, ABCB11 HDAC1 3064/4885HDAC8 3809/4885HDAC6 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.